Business model

The Magle Group’s growth focus is on profitable revenue growth generation by our own product portfolio and sales organisation. We will continuously assess potential acquisition targets to expand our product range or our sales footprint. In parallel, we will continue to drive returns from our CDMO business area by working with low risk and long-term partners and projects. We will use our returns to drive our pipeline and new products whilst strengthen our capabilities for future growth opportunity. 

Revenue flow


Development and sale of new products using the technology platform.


Royalties generated from the out licensing of the use of the technology platform.


Sale of generic active pharmaceutical ingredients to existing customers.


Provision of chemistry services to customers on a pay-for-service basis.


Production of clinical material, scale-up and supply of commercial products.